Latest revision as of 11:36, 13 May 2024

Back to Top

Page editor		Section editor
	Teja Ganta, MD Icahn School of Medicine at Mount Sinai New York, NY, USA LinkedIn		Ali Raza Khaki, MD Stanford University Palo Alto, CA, USA LinkedIn

Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.

1 regimens on this page 1 variants on this page

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

NCCN

NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Kidney Cancer.

All lines of therapy

Belzutifan monotherapy

Regimen

Study	Dates of enrollment	Evidence
Jonasch et al. 2021 (MK-6482-004)	2018-05-31 to 2019-03-29	Phase 2 (RT)

Targeted therapy

Belzutifan (Welireg) 120 mg PO once per day

Continued indefinitely

References

MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains dosing details in manuscript link to PMC article PubMed NCT03401788

@@ Line 1: / Line 1: @@
-{{#lst:Section editor transclusions|gu}}
+<span id="BackToTop"></span>
+<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
+[[#top|Back to Top]]
+</div>
+{{#lst:Editorial board transclusions|rcc}}
 Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the '''[[Renal cell carcinoma|main RCC page]]''' for other regimens.
 {| class="wikitable" style="float:right; margin-right: 5px;"
@@ Line 7: / Line 11: @@
 |}
 {{TOC limit|limit=3}}
+=Guidelines=
+'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
+==NCCN==
+*''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1440 NCCN Guidelines - Kidney Cancer].''
 =All lines of therapy=
 ==Belzutifan monotherapy {{#subobject:egac3f|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:py42s1|Variant=1}}===
 {| class="wikitable" style="width: 60%; text-align:center;"
 !style="width: 33%"|Study
-!style="width: 33%"|Years of enrollment
+!style="width: 33%"|Dates of enrollment
 !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
-|[https://doi.org/10.1056/nejmoa2103425 Jonasch et al. 2021 (MK-6482-004)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9275515/ Jonasch et al. 2021 (MK-6482-004)]
-|2018-2019
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-314-1 <span style="color:white;">ESMO-MCBS (3)</span>]'''
+|-
+|} -->
+|2018-05-31 to 2019-03-29
 | style="background-color:#91cf61" |Phase 2 (RT)
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Belzutifan (Welireg)]] 120 mg PO once per day
 '''Continued indefinitely'''
+</div></div>
 ===References===
-# '''MK-6482-004:''' Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. [https://doi.org/10.1056/nejmoa2103425 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/34818478/ Pubmed] NCT03401788
+# '''MK-6482-004:''' Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. [https://doi.org/10.1056/nejmoa2103425 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9275515/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34818478/ PubMed] [https://clinicaltrials.gov/study/NCT03401788 NCT03401788]
 [[Category:Renal cell carcinoma regimens]]
 [[Category:Biomarker-specific pages]]
 [[Category:Renal cell carcinomas]]

Difference between revisions of "Renal cell carcinoma, VHL-associated"